The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer
Cells · 18.05.2026 · 15 (10) · 925
DOI: 10.3390/cells15100925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 18.05.2026. Verfasst von Yosuk Min und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, CHA University, Seongnam 13488, Gyeonggi-Do, Republic of Korea. Hauptthemen laut MEDLINE: Cisplatin, Tumor Suppressor Protein p53, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Ministry of Science and ICT, National Research Foundation of Korea.
Abstract (Originalsprache)
Epithelial ovarian cancer (EOC) poses a challenge owing to its high rate of recurrence and drug resistance, resulting in a 5-year survival rate of 30% in advanced stages. To elucidate the molecular mechanisms underlying EOC recurrence, we analyzed transcriptome data from patients with EOC and identified elevated USP19, a deubiquitinating enzyme, as being elevated in patients without recurrence in our previous study. Single-cell RNA sequencing analysis revealed that increased USP19 expression in epithelial cells is associated with activation of apoptotic pathways, suggesting that USP19 may inhibit EOC recurrence through deubiquitination of its binding proteins. Using the protein–protein interaction database, we identified DnaJC7 as a binding partner of USP19 and confirmed their interaction experimentally. USP19-mediated deubiquitination of DnaJC7 increases its protein stability. Notably, upregulation of USP19 and DnaJC7 disrupted the interaction between p53 and MDM2, and knockdown of USP19 and DnaJC7 resulted in decreased p53 expression following cisplatin treatment. These findings highlight the therapeutic potential of enhancing the USP19-DnaJC7 axis to stabilize p53 and improve cisplatin efficacy. Promoting USP19-mediated deubiquitination by stabilizing DnaJC7 may offer a novel combination strategy to enhance the efficacy of cisplatin-based cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, CHA University, Seongnam 13488, Gyeonggi-Do, Republic of Korea.
- Department of Biomedical Science, CHA University, Seongnam 13488, Gyeonggi-Do, Republic of Korea.
- Department of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13520, Gyeonggi-Do, Republic of Korea.
- Department of Bioconvergence, CHA University, Seongnam 13488, Gyeonggi-Do, Republic of Korea.
ORCID-Profile: Yosuk Min, Hong-Beom Park, Sohyun Hwang, Kwang-Hyun Baek
Förderung
- Ministry of Education
- Ministry of Science and ICT
- National Research Foundation of Korea
Zitieren
APA
Min, Y., Kim, D., Park, H. B., Choi, H. S., Hwang, S., & Baek, K. H. (2026). The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer. Cells, 15(10), 925. https://doi.org/10.3390/cells15100925
Vancouver
Min Y, Kim D, Park HB, Choi HS, Hwang S, Baek KH. The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer. Cells. 2026;15(10):925. doi:10.3390/cells15100925
BibTeX
@article{Min2026,
author = {Min, Yosuk and Kim, Donghyeon and Park, Hong-Beom and Choi, Hae-Seul and Hwang, Sohyun and Baek, Kwang-Hyun},
title = {The USP19-DnaJC7 Axis Stabilizes p53 in Cisplatin-Treated Epithelial Ovarian Cancer},
journal = {Cells},
year = {2026},
volume = {15},
number = {10},
pages = {925},
doi = {10.3390/cells15100925}
}
EUVIMED